Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03126019
Title An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

follicular lymphoma

Therapies

Parsaclisib

Idelalisib

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN


No variant requirements are available.